Yeah, overall 525 is 70-75% in the pivotal. Adding the overlap and receptor test (vs random assignment) they could get that up higher. Also I assume some higher Ccr5 density people could be excluded in the new trial. So this would give the say 15% or so that mono does not work for another option. ViiV I believe has a once a week they wanted to partner with leonlimab.

He did say people loved leronlimab and no safety concerns at all, which excited him with cancer.

In the last mono attempted hiv trial, dolutegravir I believe, they ran a mono arm and a combo arm. The mono arm came back with resistance so they continued the combo arm to approval. I would be in favor of a similar strategy because it would almost guarantee success on the first go, without waiting to for another trial.